BIOGEN INC. Payments to Acquire Other Productive Assets
BIOGEN INC. (BIIB) reported Payments to Acquire Other Productive Assets of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2022-02-03
- BIOGEN INC. payments to acquire other productive assets for the quarter ending 2020-12-31 was $0.00.
- BIOGEN INC. payments to acquire other productive assets for the quarter ending 2020-09-30 was $0.00.
- BIOGEN INC. payments to acquire other productive assets for the quarter ending 2020-06-30 was $0.00.
- BIOGEN INC. payments to acquire other productive assets for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. payments to acquire other productive assets for fiscal 2021 was $0.00.
- BIOGEN INC. payments to acquire other productive assets for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- BIOGEN INC. payments to acquire other productive assets for fiscal 2019 was $300.00M, a 80.00% decline from fiscal 2018.
- BIOGEN INC. payments to acquire other productive assets for fiscal 2018 was $1.50B, a 25.00% increase from fiscal 2017.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 6 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-03 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $0.00 derived: sum of 2 quarters · filed 2022-02-03 | $0.00 derived: sum of 3 quarters · filed 2022-02-03 | $0.00 10-K · filed 2022-02-03 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $0.00 10-Q · filed 2020-07-22 | $0.00 derived: sum of 3 quarters · filed 2022-02-03 | $0.00 derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-23 | $0.00 derived: sum of 2 quarters · filed 2022-02-03 | $0.00 derived: sum of 3 quarters · filed 2022-02-03 | $0.00 derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $0.00 derived: sum of 2 quarters · filed 2022-02-03 | $0.00 derived: sum of 3 quarters · filed 2022-02-03 | $300.00M 10-K · filed 2022-02-03 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $300.00M 10-Q · filed 2020-10-21 | $600.00M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $300.00M 10-Q · filed 2020-07-22 | $600.00M derived: sum of 3 quarters · filed 2021-02-03 | $900.00M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $300.00M 10-Q · filed 2020-04-23 | $600.00M derived: sum of 2 quarters · filed 2021-02-03 | $900.00M derived: sum of 3 quarters · filed 2021-02-03 | $1.20B derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $600.00M derived: sum of 2 quarters · filed 2021-02-03 | $900.00M derived: sum of 3 quarters · filed 2021-02-03 | $1.50B 10-K · filed 2021-02-03 |
| 2018-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $600.00M derived: sum of 2 quarters · filed 2019-10-22 | $1.20B 10-Q · filed 2019-10-22 | $1.50B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-06-30 | $300.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $900.00M 10-Q · filed 2019-07-24 | $1.20B derived: sum of 3 quarters · filed 2020-02-06 | $1.50B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-03-31 | $600.00M 10-Q · filed 2019-04-24 | $900.00M derived: sum of 2 quarters · filed 2020-02-06 | $1.20B derived: sum of 3 quarters · filed 2020-02-06 | $1.50B derived: sum of 4 quarters · filed 2020-02-06 |
| 2017-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $600.00M derived: sum of 2 quarters · filed 2020-02-06 | $900.00M derived: sum of 3 quarters · filed 2020-02-06 | $1.20B 10-K · filed 2020-02-06 |
| 2017-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $600.00M derived: sum of 2 quarters · filed 2018-10-23 | $900.00M 10-Q · filed 2018-10-23 | $1.20B derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-06-30 | $300.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | $600.00M 10-Q · filed 2018-07-24 | $900.00M derived: sum of 3 quarters · filed 2019-02-06 | $1.20B derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-03-31 | $300.00M 10-Q · filed 2018-04-24 | $600.00M derived: sum of 2 quarters · filed 2019-02-06 | $900.00M derived: sum of 3 quarters · filed 2019-02-06 | $1.20B derived: sum of 4 quarters · filed 2019-02-06 |
| 2016-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $600.00M derived: sum of 2 quarters · filed 2019-02-06 | $900.00M derived: sum of 3 quarters · filed 2019-02-06 | $1.20B 10-K · filed 2019-02-06 |
| 2016-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $600.00M derived: sum of 2 quarters · filed 2017-10-24 | $900.00M 10-Q · filed 2017-10-24 | $1.20B derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-06-30 | $300.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $600.00M 10-Q · filed 2017-07-25 | $900.00M derived: sum of 3 quarters · filed 2018-02-01 | $1.20B derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-03-31 | $300.00M 10-Q · filed 2017-04-25 | $600.00M derived: sum of 2 quarters · filed 2018-02-01 | $900.00M derived: sum of 3 quarters · filed 2018-02-01 | $900.00M derived: sum of 4 quarters · filed 2018-02-01 |
| 2015-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $600.00M derived: sum of 2 quarters · filed 2018-02-01 | $600.00M derived: sum of 3 quarters · filed 2018-02-01 | $850.00M 10-K · filed 2018-02-01 |
| 2015-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $300.00M derived: sum of 2 quarters · filed 2016-10-26 | $550.00M 10-Q · filed 2016-10-26 | $750.00M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $250.00M 10-Q · filed 2016-07-21 | $450.00M derived: sum of 3 quarters · filed 2017-02-02 | $600.00M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-03-31 | $250.00M 10-Q · filed 2016-04-21 | $450.00M derived: sum of 2 quarters · filed 2017-02-02 | $600.00M derived: sum of 3 quarters · filed 2017-02-02 | $600.00M derived: sum of 4 quarters · filed 2017-02-02 |
| 2014-12-31 | $200.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $350.00M derived: sum of 2 quarters · filed 2017-02-02 | $350.00M derived: sum of 3 quarters · filed 2017-02-02 | $375.00M 10-K · filed 2017-02-02 |
| 2014-09-30 | $150.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $150.00M derived: sum of 2 quarters · filed 2015-10-21 | $175.00M 10-Q · filed 2015-10-21 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $25.00M 10-Q · filed 2015-07-24 | ||
| 2014-03-31 | $25.00M 10-Q · filed 2015-04-24 | |||
| 2013-12-31 | $15.00M 10-K · filed 2016-02-03 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |